Marco Ripa

4.6k total citations
47 papers, 1.1k citations indexed

About

Marco Ripa is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Marco Ripa has authored 47 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Infectious Diseases, 14 papers in Epidemiology and 13 papers in Virology. Recurrent topics in Marco Ripa's work include HIV Research and Treatment (13 papers), HIV/AIDS drug development and treatment (12 papers) and HIV/AIDS Research and Interventions (10 papers). Marco Ripa is often cited by papers focused on HIV Research and Treatment (13 papers), HIV/AIDS drug development and treatment (12 papers) and HIV/AIDS Research and Interventions (10 papers). Marco Ripa collaborates with scholars based in Italy, United States and Spain. Marco Ripa's co-authors include Antonella Castagna, Lorenzo Dagna, Moreno Tresoldi, Fabio Ciceri, Paolo Scarpellini, Mona‐Rita Yacoub, Giacomo De Luca, Emanuel Della‐Torre, Corrado Campochiaro and Giuseppe A. Ramirez and has published in prestigious journals such as PLoS ONE, Antimicrobial Agents and Chemotherapy and Archives of Physical Medicine and Rehabilitation.

In The Last Decade

Marco Ripa

42 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marco Ripa Italy	16	530	308	203	152	127	47	1.1k
Mushira A. Enani Saudi Arabia	16	758 1.4×	356 1.2×	186 0.9×	62 0.4×	114 0.9×	30	1.3k
Symeon Metallidis Greece	19	752 1.4×	230 0.7×	379 1.9×	81 0.5×	76 0.6×	101	1.6k
Marianne Kragh Thomsen Denmark	20	655 1.2×	179 0.6×	397 2.0×	78 0.5×	153 1.2×	55	1.4k
Paraskevi C. Fragkou Greece	18	704 1.3×	304 1.0×	298 1.5×	39 0.3×	145 1.1×	53	1.4k
Wendy Sligl Canada	22	456 0.9×	145 0.5×	750 3.7×	67 0.4×	60 0.5×	58	1.6k
Hyeri Seok South Korea	16	584 1.1×	190 0.6×	329 1.6×	46 0.3×	61 0.5×	59	1.1k
Maria Mazzitelli Italy	17	413 0.8×	114 0.4×	352 1.7×	87 0.6×	65 0.5×	109	1.1k
María Fernanda González-Lara Mexico	14	1.0k 2.0×	521 1.7×	267 1.3×	29 0.2×	160 1.3×	47	1.4k
Riccardo Scotto Italy	22	359 0.7×	97 0.3×	393 1.9×	39 0.3×	77 0.6×	86	1.3k
Yasemin Özsürekçi Türkiye	20	396 0.7×	117 0.4×	418 2.1×	48 0.3×	94 0.7×	135	1.3k

Countries citing papers authored by Marco Ripa

Since Specialization

Citations

This map shows the geographic impact of Marco Ripa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Ripa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Ripa more than expected).

Fields of papers citing papers by Marco Ripa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Ripa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Ripa. The network helps show where Marco Ripa may publish in the future.

Co-authorship network of co-authors of Marco Ripa

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Ripa. A scholar is included among the top collaborators of Marco Ripa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Ripa. Marco Ripa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ripa, Marco, et al.. (2025). Naegleria fowleri Infections: Bridging Clinical Observations and Epidemiological Insights. Journal of Clinical Medicine. 14(2). 526–526. 1 indexed citations

Ripa, Marco, Laura Galli, Paola Cinque, et al.. (2025). The INfectious DIsease REgistry BIObank (INDI-REBIO): protocol for the design and implementation of a single-centre, prospective registry and biobank in a tertiary care centre in Italy for advancing infectious disease research. BMJ Open. 15(8). e091113–e091113.

Mojica, María F., et al.. (2025). How do I manage a patient with Stenotrophomonas maltophilia infection?. Clinical Microbiology and Infection. 31(8). 1291–1297. 2 indexed citations

Raccagni, Angelo Roberto, Laura Galli, Martina Ranzenigo, et al.. (2024). Trends of Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolates Between 2012 and 2023: Results From an Open Italian Cohort. Sexually Transmitted Diseases. 51(8). 540–544. 4 indexed citations

Ranzenigo, Martina, Alessandra Marzi, Chiara Oltolini, et al.. (2024). Combination of High-Dose Daptomycin and Ceftriaxone for Cardiac Implantable Electronic Device Infections: A 10-Year Experience. Clinical Therapeutics. 46(10). 819–821. 1 indexed citations

Margalit, Ili, Giusy Tiseo, Marco Ripa, et al.. (2023). Real-life experience with remdesivir for treatment of COVID-19 among older adults: a multicentre retrospective study. Journal of Antimicrobial Chemotherapy. 78(6). 1505–1509. 5 indexed citations

Ramirez, Giuseppe A., Marco Ripa, Samuele E. Burastero, et al.. (2023). Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses. Microorganisms. 11(2). 346–346. 22 indexed citations

Nozza, Silvia, Angelo Roberto Raccagni, Laura Galli, et al.. (2022). Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohort. BMJ Open. 12(12). e067261–e067261. 6 indexed citations

Zangrillo, Alberto, Alessandro Belletti, Diego Palumbo, et al.. (2021). One-Year Multidisciplinary Follow-Up of Patients With COVID-19 Requiring Invasive Mechanical Ventilation. Journal of Cardiothoracic and Vascular Anesthesia. 36(5). 1354–1363. 39 indexed citations

10.

Ripa, Marco, Stefania Chiappetta, Barbara Castiglioni, et al.. (2021). Impact of surgical timing on survival in patients with infective endocarditis: a time-dependent analysis. European Journal of Clinical Microbiology & Infectious Diseases. 40(6). 1319–1324. 1 indexed citations

11.

Campochiaro, Corrado, Emanuel Della‐Torre, Giulio Cavalli, et al.. (2020). Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. European Journal of Internal Medicine. 76. 43–49. 285 indexed citations

12.

Natalello, G., Giacomo De Luca, Laura Gigante, et al.. (2020). Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. Microvascular Research. 133. 104071–104071. 54 indexed citations

13.

Tascini, Carlo, Vittorio Attanasio, Marco Ripa, et al.. (2019). Ceftobiprole for the treatment of infective endocarditis: A case series. Journal of Global Antimicrobial Resistance. 20. 56–59. 34 indexed citations

14.

Ramirez, Giuseppe A., Mona‐Rita Yacoub, Marco Ripa, et al.. (2018). Eosinophils from Physiology to Disease: A Comprehensive Review. BioMed Research International. 2018. 1–28. 191 indexed citations

15.

Gianotti, Nicola, Laura Galli, Marco Ripa, et al.. (2018). Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen. International Journal of Antimicrobial Agents. 52(4). 492–499. 10 indexed citations

16.

Rodríguez-Núñez, Olga, Marco Ripa, Laura Morata, et al.. (2018). Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. Journal of Global Antimicrobial Resistance. 15. 136–139. 44 indexed citations

17.

Gianotti, Nicola, Andrea Poli, Silvia Nozza, et al.. (2017). Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients. BMC Infectious Diseases. 17(1). 723–723. 5 indexed citations

18.

Nozza, Silvia, Laura Galli, Valentina Svicher, et al.. (2016). 48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study.. PubMed. 39(3). 192–196.

19.

Ripa, Marco, Manuela Pogliaghi, Stefania Chiappetta, et al.. (2016). Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up. Journal of Clinical Virology. 85. 86–89. 1 indexed citations

20.

Nozza, Silvia, Laura Galli, Andrea Antinori, et al.. (2014). Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study. Clinical Microbiology and Infection. 21(5). 510.e1–510.e9. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact